Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

NCT06027983 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

HER2+ Advanced Breast Cancer
Other Solid Tumors

Interventions

DRUG: Chimeric receptor T-cells + Trastuzumab
DRUG: Fludarabine and Cyclophosphosphamide

Sponsor

National University Hospital, Singapore